Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 17;11(1):e006226. doi: 10.1136/jitc-2022-006226

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

In vivo therapeutic mechanism of M@P-SOP with HIFU. (A) Immunofluorescence staining of CRT in tumor slices after various treatments. (B, C) FCM analysis of DCs maturation in lymph nodes (B) and spleen (C) initiated by various treatments in vivo. (D) Immunofluorescence images of tumor slices displaying population of CD8-positive cells for various groups of mice. (E, F) Statistical data of (B, C) respectively (n=3, one-way ANOVA, ****p<0.0001). ANOVA, analysis of variance; DC, dendritic cell; FCM, flow cytometry; CRT, calreticulin; HIFU, high-intensity focused ultrasound; ns, not significant.